symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
NRSN,0.5411,0,81131,7371405,0,0.5-2.91,0.0111,NeuroSense Therapeutics Ltd.,USD,0001875091,IL0011809592,M74240108,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.neurosense-tx.com,"NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.",Mr. Alon  Ben-Noon,Healthcare,IL,14,972 9 799 6183,Building B,Herzliya,,4672562,,0,https://financialmodelingprep.com/image-stock/NRSN.png,2021-12-09,False,False,True,False,False
